1-4 of 4
daunorubicin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Clinical Trials & Observations
Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2021) 5 (13): 2775–2787.
https://doi.org/10.1182/bloodadvances.2021004233
Published: 2021
Includes: Supplemental data
Journal Articles

Combination of dasatinib with chemotherapy in previously untreated core binding factor acute myeloid leukemia: CALGB 10801

Clinical Trials & Observations
Guido Marcucci, Susan Geyer, Kristina Laumann, Weiqiang Zhao, Donna Bucci, Geoffrey L. Uy, William Blum, Ann-Kathrin Eisfeld, Timothy S. Pardee, Eunice S. Wang, Wendy Stock, Jonathan E. Kolitz, Jessica Kohlschmidt, Krzysztof Mrózek, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson
Journal: Blood Advances
Blood Adv (2020) 4 (4): 696–705.
https://doi.org/10.1182/bloodadvances.2019000492
Published: 2020
Journal Articles

Aberrant GSK3β nuclear localization promotes AML growth and drug resistance

James J. Ignatz-Hoover, Victoria Wang, Nathan M. Mackowski, Anne J. Roe, Isaac K. Ghansah, Masumi Ueda, Hillard M. Lazarus, Marcos de Lima, Elisabeth Paietta, Hugo Fernandez, Larry Cripe, Martin Tallman, David N. Wald
Journal: Blood Advances
Blood Adv (2018) 2 (21): 2890–2903.
https://doi.org/10.1182/bloodadvances.2018016006
Published: 2018
Includes: Supplemental data
Journal Articles

The role of targeted therapy in the management of patients with AML

Clinical Trials & Observations
Alexander E. Perl
Journal: Blood Advances
Blood Adv (2017) 1 (24): 2281–2294.
https://doi.org/10.1182/bloodadvances.2017009829
Published: 2017